Stocks · News reference
RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the University of Oklahoma (OU), has received $2.9 million in
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RedHill Biopharma Announces Deal To Acquire Global Rebyota And U.S. Clenpiq Commercialization Rights From Ferring For $12M Upfront, Plus Milestones And Tiered Royalties
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
The nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.